Serial Metabolic Measurements and Conversion to Type 2 Diabetes in the West of Scotland Coronary Prevention Study
The DOI matches its Crossref record, with a small difference in title or year; 30 of the 30 references it cites were found in a registry or an index.
Abstract
To examine metabolic changes (lipids, liver enzymes, blood pressure, and weight) potentially associated with conversion to diabetes, we analyzed serial glucose and other metabolic measures obtained every 6 months within the West of Scotland Coronary Prevention Study trial. Changes in parameters for 86 men who converted to new-onset diabetes (“converters”: two consecutive glucose levels ≥7 mmol/l) were compared with 860 “nonconverters” matched for age and treatment allocation. Eighteen months before the diagnosis, converters to diabetes had elevated (P < 0.01) fasting glucose, weight, triglyceride, alanine aminotransferase (ALT), blood pressure, and white cell count and lower HDL cholesterol compared with nonconverters. The mean (SD) increase in fasting glucose over 18 months in converters was 1.80 (1.52) mmol/l, compared with 0.10 (0.57) in nonconverters. Of parameters measured, only ALT (P = 0.0005) and triglyceride (P = 0.030) increased significantly more over the 18 months in converters compared with nonconverters, but neither parameter increased significantly in nonconverters with high baseline glucose concentrations (>6.1 mmol/l). Finally, only sustained increases in ALT predicted a higher risk for diabetes. We conclude that a relatively rapid rise in fasting glucose levels is frequent in converters to diabetes and that associated increases over time in ALT and potentially triglyceride suggest hepatic fat accumulation as a contributing factor for conversion to diabetes in men at risk.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Evidence from epidemiological studies with repeated measures of glucose and insulin parameters over many years suggests that the development of T2DM is a gradual process 54, 55.”
From Type 2 diabetes mellitus and psychological stress — a modifiable risk factor (2017) · cites this paper as [54]
In the citing paper
“As evidenced by studies with repeat measures of glucose levels, insulin sensitivity and insulin secretion, the development of diabetes from NGT is a continuous process.35,36,40,41”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [35]
In the citing paper
“This pattern of glycaemic changes was confirmed by others.35,40,41”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [35]
In the citing paper
“Most recent attempts to improve diabetes prediction using measurements from genetics and transcriptomics have not shown significant improvements in predictive performance but it is unknown whether serial measurements may decrease variations in non-genetic biomarkers allowing for a more precise estimation of their levels.34–36”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [35]
Citations
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Self-citationPREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
(2006) · The Lancet · doi:10.1016/s0140-6736(06)69420-8 · Cited by 1,706 · cited 1×
“With respect to drug treatment, glitazones lower hepatic fat directly and lower liver enzyme levels (24,25), in particular ALT, as observed in the rosiglitazone arm of the recently reported DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) study (26), whereas metformin has been variably…”
BackgroundSattar, N., Gaw, A., Scherbakova, O., Ford, I., O’Reilly, D. S. J., Haffner, S. M., Isles, C., Macfarlane, P. W., Packard, C. J., Cobbe, S. M., et al. (2003) · Circulation · doi:10.1161/01.cir.0000080897.52664.94 · Cited by 1,506 · cited 1×
“Such information, in conjunction with extensive baseline measures, has allowed us to link baseline metabolic syndrome status (5), C-reactive protein (6), and From the (1)Department of Vascular Biochemistry, University of Glasgow, Glasgow, Scotland; the (2)Robertson Centre for Biostatistics, University of Glasgow, Glas…”
BackgroundSelf-citationMechanism of hepatic insulin resistance in non-alcoholic fatty liver disease
Samuel, V. T., Liu, Z.-X., Qu, X., Elder, B. D., Bilz, S., Befroy, D., Romanelli, A. J., & Shulman, G. I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313478200 · Cited by 1,322 · cited 1×
“Excess fat in liver, via accumulation of total fatty acyl-CoA, impairs insulinstimulated IRS-1 and IRS-2 tyrosine phosphorylation and ultimately decreases insulin activation of glycogen synthase and promotes increased gluconeogenesis (16).”
BackgroundPetersen, K. F., Dufour, S., Befroy, D., Lehrke, M., Hendler, R. E., & Shulman, G. I. (2005) · Diabetes · doi:10.2337/diabetes.54.3.603 · Cited by 911 · cited 1×
“(20) noted that moderate weight loss with very low–fat diet normalizes fasting hyperglycemia in patients with poorly controlled type 2 diabetes by mobilizing a relatively small pool of intrahepatic lipid.”
BackgroundEffect of ramipril on the incidence of diabetes
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa065061 · Cited by 737 · cited 1×
“Finally, although ramipril did not significantly reduce progression to diabetes in subjects at risk, it did significantly increase regression to normoglycemia and was associated with a significantly greater reduction in ALT concentrations in the 1st year compared with placebo (29).”
BackgroundFreeman, D. J., Norrie, J., Caslake, M. J., Gaw, A., Ford, I., Lowe, G. D. O., O’Reilly, D. S. J., Packard, C. J., Sattar, N., & for the West of Scotland Coronary Prevention Study Group (2002) · Diabetes · doi:10.2337/diabetes.51.5.1596 · Cited by 728 · cited 1×
“Such information, in conjunction with extensive baseline measures, has allowed us to link baseline metabolic syndrome status (5), C-reactive protein (6), and From the (1)Department of Vascular Biochemistry, University of Glasgow, Glasgow, Scotland; the (2)Robertson Centre for Biostatistics, University of Glasgow, Glas…”
BackgroundSelf-citationVozarova, B., Stefan, N., Lindsay, R. S., Saremi, A., Pratley, R. E., Bogardus, C., & Tataranni, P. A. (2002) · Diabetes · doi:10.2337/diabetes.51.6.1889 · Cited by 717 · cited 1×
“However, because cholesterol is not generally predictive of diabetes and because others have shown higher ALT levels to predict diabetes (8,10,11), we feel such limitations are not significant concerns.”
BackgroundBugianesi, E., Gentilcore, E., Manini, R., Natale, S., Vanni, E., Villanova, N., David, E., Rizzetto, M., & Marchesini, G. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41583.x · Cited by 691 · cited 1×
“With respect to drug treatment, glitazones lower hepatic fat directly and lower liver enzyme levels (24,25), in particular ALT, as observed in the rosiglitazone arm of the recently reported DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) study (26), whereas metformin has been variably…”
Background
Cited by
Prediabetes: a high-risk state for diabetes development
Tabák, A. G., Herder, C., Rathmann, W., Brunner, E. J., & Kivimäki, M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60283-9 · Cited by 2,958
Tabák, A. G., Jokela, M., Akbaraly, T. N., Brunner, E. J., Kivimäki, M., & Witte, D. R. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60619-x · Cited by 898
Fatty Liver: A Novel Component of the Metabolic Syndrome
Kotronen, A., & Yki-Järvinen, H. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.147538 · Cited by 797
Modeling type 2 diabetes in rats using high fat diet and streptozotocin
Skovsø, S. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12235 · Cited by 596
From the metabolic syndrome to NAFLD or vice versa?
Vanni, E., Bugianesi, E., Kotronen, A., De Minicis, S., Yki-Järvinen, H., & Svegliati-Baroni, G. (2010) · Digestive and Liver Disease · doi:10.1016/j.dld.2010.01.016 · Cited by 497
Metadata
- Authors
- Sattar, N., McConnachie, A., Ford, I., Gaw, A., Cleland, S. J., Forouhi, N. G., McFarlane, P., Shepherd, J., Cobbe, S., & Packard, C.
- Affiliations
- University of Glasgow (GB)
- Stobhill Hospital (GB)
- MRC Epidemiology Unit (GB)
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2007-04-01
- Volume
- 56
- Issue
- 4
- Pages
- 984-991
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2103040969
- Cited by
- 127
- References
- 30
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 4 · 2023: 3 · 2022: 6 · 2021: 3 · 2020: 5 · 2019: 2 · 2018: 2 · 2017: 7 · 2016: 7 · 2015: 8 · 2014: 7 · 2013: 11 · 2012: 9
- FWCI
- 9.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Keywords
- type 2 diabetes, prediabetes, fasting blood glucose, alanine aminotransferase, triglycerides, hepatic lipid accumulation, liver enzymes, diabetes risk prediction, men, WOSCOPS, HDL cholesterol, blood pressure, body weight
- MeSH terms
- Adipose Tissue, Alanine Transaminase, Aspartate Aminotransferases, Blood Glucose, Body Weight, Coronary Disease, Diabetes Mellitus, Type 2, Humans, Lipids, Liver, Male, Scotland, Triglycerides, Incidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serial Metabolic Measurements and Conversion to Type 2 Diabetes in the West of Scotland Coronary Prevention Study. https://app.cochat.ai/papers/10.2337/db06-1256
- The paper
- Sattar, N., McConnachie, A., Ford, I., Gaw, A., Cleland, S. J., Forouhi, N. G., McFarlane, P., Shepherd, J., Cobbe, S., & Packard, C. (2007). Serial Metabolic Measurements and Conversion to Type 2 Diabetes in the West of Scotland Coronary Prevention Study. Diabetes. https://doi.org/10.2337/db06-1256
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.